Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival
Steinmetz, Hans Tilman, Toczek-Thiel, J., Lipke, J., Liersch, R., Sauer, A., Tesch, H., Heßling, J., Totzke, U., Schmitz, S.
Published in Leukemia & lymphoma (03.07.2023)
Published in Leukemia & lymphoma (03.07.2023)
Get full text
Journal Article
PF547 FACTORS ASSOCIATED WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME (MDS). DATA FROM THE REGULAR CARE MDS‐REGISTRY IN GERMANY
Steinmetz, H.T., Toczek‐Thiel, J., Hellmich, M., Lipke, J., Liersch, R., Sauer, A., Tesch, H., Hessling, J., Schmitz, S.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
FACTORS ASSOCIATED WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME (MDS). DATA FROM THE REGULAR CARE MDS-REGISTRY IN GERMANY: PF547
Steinmetz, H. T., Toczek-Thiel, J., Hellmich, M., Lipke, J., Liersch, R., Sauer, A., Tesch, H., Hessling, J., Schmitz, S.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article